Topics
Researcher Unno from Pharmacology BU to Present a Poster at the 84th Annual Meeting of the Japanese Cancer Association
2025.09.04
Our researcher, Satoko Unno from the Pharmacology Business Unit, will present a poster at the 84th Annual Meeting of the Japanese Cancer Association, to be held from September 25 to 27, 2025, in Kanazawa city, Ishikawa prefecture, Japan.
If you plan to attend the conference, we encourage you to join the session and hear the presentation.
Conference Name: the 84th Annual Meeting of the Japanese Cancer Association
Date & Time: Saturday, September 27th, 16:15 – 17:00 (JST)
Location: Motenashi Dome Underground Plaza
Title: Immune Cell function and Effect of Immune Checkpoint Inhibitor in Freshly Dispersed Human Tumors
Poster number: P-3156
Presenter: Satoko Unno, Pharmacology Business Unit
Presentation Summary
Human cancer tissues contain not only tumor cells but also a variety of immune cells, and their interactions shape the complex tumor microenvironment (TME). A deeper understanding of immune responses within the TME is essential for the development of novel immunotherapies.
In this study, fresh human cancer tissues were enzymatically dissociated into single-cell suspensions, and the composition and function of tumor-infiltrating immune cells (TILs) were analyzed by flow cytometry. We observed infiltration of heterogeneous immune cell populations, including PD-1–high CD8⁺ and CD4⁺ T cells as well as tumor-associated macrophages (TAMs).
Upon anti-CD3 antibody stimulation, TILs produced IFNγ, which served as a functional readout of T cell responsiveness and reflected the immune status of the TME. This functional assay may therefore be valuable in evaluating immunological competence within tumors.
In addition, we also present data on the effects of immune checkpoint inhibitors, which provide further insights into the development of future immunotherapies.
Axcelead DDP’s Soulution
At Axcelead DDP, we have established a unique system for obtaining fresh human cancer tissues, which serve as an extremely valuable tool in drug discovery research. Using these fresh cancer tissues, our in vitro evaluation system for evaluating immune responses tumor tissues is highly useful for the discovery and development of novel cancer immunotherapies.
Axcelead DDP has access to a wide range of human tissues and cell types beyond cancer. Utilizing comprehensive omics analyses, we support research into disease mechanisms and biomarker discovery.
If you are interested in any particular tissues or evaluation systems, please feel free to contact us.
Satoko Unno, Pharmacology Business Unit
Engaged in drug discovery research as a pharmacologist, focusing on immunology and inflammatory diseases at Takeda Pharmaceutical Company.
Joined to Axcelead Drug Discovery Partners Inc. in 2017 and has since been involved in pharmacological studies in immunology and cancer immunotherapy.

